The 15 trials that reported the effect of GLP-1 on liver fat content included 13 trials in persons with type 2 diabetes, five trials in patients with NAFLD, two trials in patients without type 2 diabetes, and 10 trials in patients without NAFLD. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.